Dysregulated microRNAs in prostate cancer: In silico prediction and in vitro validation

Document Type : Original Article

Authors

1 Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Bioinformatics Research Center, Mashhad University of Medical Science, Mashhad, Iran

Abstract

Objective(s): MicroRNAs, which are micro-coordinators of gene expression, have been recently investigated as a potential treatment for cancer. The study used computational techniques to identify microRNAs that could target a set of genes simultaneously. Due to their multi-target-directed nature, microRNAs have the potential to impact multiple key pathways and their pathogenic cross-talk. 
Materials and Methods: We identified microRNAs that target a prostate cancer-associated gene set using integrated bioinformatics analyses and experimental validation. The candidate gene set included genes targeted by clinically approved prostate cancer medications. We used STRING, GO, and KEGG web tools to confirm gene-gene interactions and their clinical significance. Then, we employed integrated predicted and validated bioinformatics approaches to retrieve hsa-miR-124-3p, 16-5p, and 27a-3p as the top three relevant microRNAs. KEGG and DIANA-miRPath showed the related pathways for the candidate genes and microRNAs
Results: The Real-time PCR results showed that miR-16-5p simultaneously down-regulated all genes significantly except for PIK3CA/CB in LNCaP; miR-27a-3p simultaneously down-regulated all genes significantly, excluding MET in LNCaP and PIK3CA in PC-3; and miR-124-3p could not down-regulate significantly PIK3CB, MET, and FGFR4 in LNCaP and FGFR4 in PC-3. Finally, we used a cell cycle assay to show significant G0/G1 arrest by transfecting miR-124-3p in LNCaP and miR-16-5p in both cell lines. 
Conclusion: Our findings suggest that this novel approach may have therapeutic benefits and these predicted microRNAs could effectively target the candidate genes.

Keywords

Main Subjects

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: CA Cancer J Clin 2021; 71:209-249.
2. Rezaei S, Mahjoubin Tehran M, Sahebkar A, Jalili A, Aghaee‐Bakhtiari SH. Androgen receptor‐related micro RNAs in prostate cancer and their role in antiandrogen drug resistance. J Cell Physiol 2020; 235:3222-3234.
3. Leung DK-W, Chiu PK-F, Ng C-F, Teoh JY-C. Novel strategies for treating castration-resistant prostate cancer. Biomedicines 2021; 9:339-Last page.
4. Rezaei S, Jalili A, Aghaee-Bakhtiari SH, Sahebkar A. Decoy oligodeoxynucleotide technology: an emerging paradigm for breast cancer treatment. Drug Discov. Today 2020; 25:195-200.
5. Mahjoubin-Tehran M, Rezaei S, Jalili A, Sahebkar A, Aghaee-Bakhtiari SH. A comprehensive review of online resources for microRNA–diseases associations: the state of the art. Brief Bioinform 2022; 23:bbab381.
6. von Brandenstein M, Bernhart SH, Pansky A, Richter C, Kohl T, Deckert M, et al. Beyond the 3′ UTR binding–microRNA-induced protein truncation via DNA binding. Oncotarget 2018; 9:32855.
7. Krupa R, Malecki W, Czarny P, Strycharz J, Jablkowski M, Kordek R, et al. MicroRNA profile and iron-related gene expression in hepatitis C-related hepatocellular carcinoma: a preliminary study. Arch Med Sci: AMS 2021; 17:1175-1183.
8. Bajan S, Hutvagner G. RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells 2020; 9:137-163.
9. Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database. Nucleic Acids Res. 2020; 48:D148-D154.
10. Monga I, Kumar M. Computational resources for prediction and analysis of functional miRNA and their targetome. Computational Biology of Non-Coding RNA 2019: pp 215-250.
11. Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 2014; 6:39-51.
12. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 2010; 33:609-613.
13. Sonpavde GP, Pond GR, Fizazi K, de Bono JS, Basch EM, Scher HI, et al. Cabozantinib for progressive metastatic castration-resistant prostate cancer following docetaxel: combined analysis of two phase 3 trials. Eur Urol Oncol 2020; 3:540-543.
14. Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, et al. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs 2018; 36:919-926.
15. Choi YJ, Kim HS, Park SH, Kim BS, Kim KH, Lee HJ, et al. Phase II study of Dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05). Cancer Res Treat 2018; 50:1252-1259.
16. Rescigno P, de Bono J, Aparicio A, Chowdhury S, Twardowski P, Dawson N, et al. Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K) β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 2017; 28:v273.
17. Nandana S, Chung LW. Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. AJCEU 2014; 2:92-101.
18. Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget 2014; 5:7217-7259.
19. Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, et al. GeneMANIA update 2018. Nucleic Acids Res 2018; 46:W60-W64.
20. Maere S, Heymans K, Kuiper M. BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005; 21:3448-3449.
21. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 2022; 50:W216-W221.
22. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009; 4:44-57.
23. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28:27-30.
24. Karagkouni D, Paraskevopoulou MD, Chatzopoulos S, Vlachos IS, Tastsoglou S, Kanellos I, et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions. Nucleic Acids Res. 2018; 46:D239-D245.
25. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognitionrget recognition. Nat Genet 2007; 39:1278-1284.
26. McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, et al. The biochemical basis of microRNA targeting efficacy. Science 2019; 366:eaav1741.
27. Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019; 20:1-10.
28. Hsu JB-K, Chiu C-M, Hsu S-D, Huang W-Y, Chien C-H, Lee T-Y, et al. miRTar: an integrated system for identifying miRNA-target interactions in human. BMC bioinformatics 2011; 12:1-12.
29. Mahjoubin-Tehran M, Aghaee-Bakhtiari SH, Sahebkar A, Butler AE, Oskuee RK, Jalili A. In silico and in vitro analysis of microRNAs with therapeutic potential in atherosclerosis. Sci Rep 2022; 12:20334.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods 2001; 25:402-408.
31.Kalofonou F, Sita-Lumsden A, Leach D, Fletcher C, Waxman J, Bevan CL. MiR-27a-3p: An AR-modulatory microRNA with a distinct role in prostate cancer progression and therapy. ASCO; 2020.
32. Zhang J, Cao Z, Yang G, You L, Zhang T, Zhao Y. MicroRNA-27a (miR-27a) in solid tmors: a review based on mechanisms and clinical observations. Front Oncol 2019; 9:893.
33. Li Y, Li J, Sun X, Chen J, Sun X, Zheng J, et al. MicroRNA‑27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor. Oncol Lett 2016; 11:4217-4223.
34. Jiang Y, Duan Y, Zhou H. MicroRNA-27a directly targets KRAS to inhibit cell proliferation in esophageal squamous cell carcinoma. Oncol Lett 2015; 9:471-477.
35. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget 2013; 4:346-361.
36. Jafari Najaf Abadi MH, Khorashadizadeh M, Zarei Jaliani H, Jamialahmadi K, Aghaee‐Bakhtiari SH. miR‐27 and miR‐124 target AR coregulators in prostate cancer: Bioinformatics and in vitro analysis. Andrologia 2022:e14497.
37. Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013; 32:4130-4138.
38. Shi X-B, Xue L, Ma A-H, Tepper CG, Gandour-Edwards R, Kung H-J, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013; 32:4130-4138.
39. Ged Y, Horgan AM. Management of castrate-resistant prostate cancer in older men. J Geriatr Oncol 2016; 7:57-63.
40. Wu Z, Huang W, Chen B, Bai P, Wang X, Xing J. Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21:2338-2345.
41. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007; 27:2240-2252.
42. miR-15a and miR-16-1 microRNAs are prostate cancer suppressors. Nat Clin Pract Urol. 2009; 6:4-4.
43. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010; 17:215-220.
44. Jin W, Chen F, Wang K, Song Y, Fei X, Wu B. miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-β signaling pathway. Biomed Pharmacother 2018; 104:637-644.
45. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14:1271-1277.
Iranian Journal of Basic Medical Sciences
Volume 27, Issue 5
May 2024
Pages 611-620

Files

Share

How to cite

Statistics